Cargando…
Biophysical Characterization of LTX-315 Anticancer Peptide Interactions with Model Membrane Platforms: Effect of Membrane Surface Charge
LTX-315 is a clinical-stage, anticancer peptide therapeutic that disrupts cancer cell membranes. Existing mechanistic knowledge about LTX-315 has been obtained from cell-based biological assays, and there is an outstanding need to directly characterize the corresponding membrane-peptide interactions...
Autores principales: | Koo, Dong Jun, Sut, Tun Naw, Tan, Sue Woon, Yoon, Bo Kyeong, Jackman, Joshua A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501188/ https://www.ncbi.nlm.nih.gov/pubmed/36142470 http://dx.doi.org/10.3390/ijms231810558 |
Ejemplares similares
-
Understanding the Biophysical Interaction of LTX-315 with Tumoral Model Membranes
por: Klaiss-Luna, Maria C., et al.
Publicado: (2022) -
LTX-315 (Oncopore™): A short synthetic anticancer peptide and novel immunotherapeutic agent
por: Camilio, Ketil André, et al.
Publicado: (2014) -
The oncolytic peptide LTX-315 triggers immunogenic cell death
por: Zhou, H, et al.
Publicado: (2016) -
The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization
por: Zhou, Heng, et al.
Publicado: (2015) -
LTX-315 – a promising novel antitumor peptide and immunotherapeutic agent
por: Zweytick, Dagmar
Publicado: (2019)